Home > Pressrelease > Bioreactors Market size to exceed $23bn by 2030

Bioreactors Market size to exceed $23bn by 2030

  • Published Date: May 26, 2022

Bioreactors Market Size is set to surpass USD 23 billion by 2030, according to a new research report by Global Market Insights Inc.

Growing number of initiatives for disease awareness along with continuous development in personalized medicine across the globe will foster the market demand. Personalized medicine helps healthcare professionals to deliver the best therapy for their patients therefore, adoption of these medicines is rapidly increasing. Moreover, introduction of personalized medicine increases the patient adherence to treatment and also increase physician-patient engagement towards patient centered care. Bioreactors provide a specific environment for the discovery and production of such therapeutics as well as offer several benefits such as scaled up or down the molecule production as per requirement.

Increased focus on research and development of innovative vaccine against COVID-19 owing to high incidence and mortality rate has fueled the bioreactors market growth. There has been high demand for bioreactors for research and development of several potential therapeutics and vaccines for COVID-19 at several research institutes and biopharmaceutical manufacturers. Thus, with rising need for vaccine approval and distribution will drive the business landscape.

Increasing demand for several therapeutics to cater to high patient pool will boost the adoption of bioreactors for better productivity

The biopharmaceuticals industry is estimated to grow enormously due to high disease burden worldwide. Rising prevalence rate of several chronic disorders along with severe infections globally will augment the market revenue. As per the Centers for Disease Control and Prevention (CDC), in the U.S., chronic diseases are among the leading causes of death. Six out of ten people suffer from a chronic disease in the country. Rise in number of such chronic diseases has offered lucrative growth opportunities for biopharmaceutical industry, especially for vaccines and therapeutics. Thus, biopharmaceutical manufacturers are adopting developed bioreactor systems to enhance productivity.

High adoption of single-use bioreactors for development of preventive therapeutics will accelerate the industry trends

Bioreactors market from single-use bioreactors segment accounted for USD 1.6 billion in 2021. Increasing adoption of single-use bioreactors for vaccine production and research against a wide array infectious diseases including COVID-19 will augment the market outlook. For instance, some universities are using Applikon's single-use bioreactors to develop multiple viral vaccines simultaneously while maintaining optimal conditions. Growing customer preferences towards single use bioreactors owing to several benefits provided to researchers will result in a higher adoption rate.

Robust properties of bacterial cells in therapeutic production will fuel the industry expansion

Bacterial cells segment is predicted to witness 12.8% CAGR during the forecast timeframe. Customizable and technologically advanced bioreactors have aided the growing culture of bacterial cells and various other cell types. Bacterial cells are being utilized for production of numerous pharmaceutical therapeutics. The demand for precise and effective medicines has increased as the incidence and prevalence of several rare and chronic diseases has increased. Bacterial cells are also robust and resistant to shear damage, thus they are widely used by various manufacturers and research institutes, thereby, stimulating segment revenue.

Browse key industry insights spread across 205 pages with 299 market data tables & 20 figures & charts from the report, Bioreactors Market Analysis By Product Type (Single-use, Reusable), Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), Usage (Developmental, Pre-clinical & Clinical, Commercial Production), End-use (R&D Organizations, Biopharma Manufacturers, Contract Manufacturing Organizations [CMOs]), Industry Analysis, Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:

Rising adoption of monoclonal antibodies owing to several preventive and therapeutic applications will bolster the market demand

Bioreactors market from monoclonal antibodies (mAb) segment was valued at USD 2 billion in 2021. Monoclonal antibodies are widely used in targeted therapy for cancer treatment. mAbs are at the forefront of medical research due to their expanding diagnostic and therapeutic applications, These antibodies can be manufactured with ease and purity at high product concentrations. Moreover, the availability of specialized bioreactor systems and solutions for mAbs and as per end-user need will impel the segment expansion.

Broad applications of reusable bioreactors along with expanding pharmaceutical industry will strengthen product adoption for commercial production

Bioreactors market from commercial production segment is estimated to proceed at 11.9% CAGR during forecast timeframe. Increasing chronic disease burden as well as the introduction of new organizations into the industry will boost the pharmaceutical sector. Thus, rise in infectious and chronic diseases, commercial production is being influenced by mass production of vaccines and treatments will spur the industry statistics. Additionally, reusable bioreactors are convenient for the production of such products thus, high cost associated with reusable bioreactors will enhance the segment revenue size.

Increase in government investments for R&D activities will fortify the demand for bioprocessing systems

Research and development (R&D) organizations segment is predicted to proceed at 13.6% CAGR during the forecast timeline. Rising investments and spending for research and development activities for chronic diseases around the world will positively influence the adoption of bioreactors in R&D organizations. The project is aimed at better understanding and management of several noncommunicable diseases such as cancer, respiratory disorders, diabetes, and cardiovascular diseases among others. Such initiatives as well as increasing focus on novel drug development will accelerate the market trends.

Large number of research institutes in Europe will spur the business potential

Europe bioreactors market accounted for more than 38% revenue share in 2021. Strong presence of research organizations in the region that are rapidly adopting technologically advanced bioreactors, especially those are disposable in nature. The regional companies also manufacture innovative therapeutics in bulk, including as stem cells, vaccines, monoclonal antibodies, and others. This creates significant potential for several bioprocessing equipment such as bioreactors. In addition, presence of various bioreactor system suppliers will propel market forecasts.

Innovative product launches will strengthen companies’ market footprints

Some of the notable market players involved in the bioreactors market include Danaher Corporation, Merck Group, Thermo Fisher Scientific, Pierre Guerin SAS (Engie), Getinge (Applikon Biotechnology), Cellexus Ltd, CESCO Bioengineering Co. Ltd, Bbi Biotech, Shanghai Bailun Biotechnology co., Ltd., Sartorius Group Eppendorf AG, PBS Biotech, Eppendorf AG, Solaris Biotech Solutions, CerCell Aps and GEA Group Aktiengesellschaft. These industry players are incorporating several growth strategies such as acquisition and product launches to strengthen their product portfolio and broaden their market share.

Authors: Sumant Ugalmugle, Rupali Swain